Mikael S. Thomsen

CYP2C8 and CYP3A4 are the principal enzymes involved in the human <i>in vitro</i> biotransformation of the insulin secretagogue repaglinide

Tanja Busk Bidstrup, Inga Bjørnsdottir, Ulla G. Sidelmann et al. · British Journal of Clinical Pharmacology · 2003 · 203 citations · Full text

Influence of Drugs Interacting with CYP3A4 on the Pharmacokinetics, Pharmacodynamics, and Safety of the Prandial Glucose Regulator Repaglinide

Vibeke Hatorp, Kristian T. Hansen, Mikael S. Thomsen · The Journal of Clinical Pharmacology · 2003 · 106 citations

Healthy Subjects, Pharmacotherapy, Insulin Signaling +16

Clinical Pharmacokinetics of Artemether and Lumefantrine (Riamet??)

Gilbert Lef vre, Mikael S. Thomsen · Clinical Drug Investigation · 1999 · 97 citations

Pharmacological Study, Pharmacology, Clinical Pharmacokinetics +2

Pharmacokinetic interaction trial between co-artemether and mefloquine

Gilbert Lefèvre, M. Bindschedler, Farkad Ezzet et al. · European Journal of Pharmaceutical Sciences · 2000 · 67 citations

Medicine, Pharmacotherapy, Pharmacokinetic Interaction Trial +2

Cytochrome P4502E1 Inhibition by Propylene Glycol Prevents Acetaminophen (Paracetamol) Hepatotoxicity in Mice without Cytochrome P4501A2 Inhibition

Mikael S. Thomsen, Steffen Loft, Dean W. Roberts et al. · Pharmacology & Toxicology · 1995 · 50 citations

Pharmacotherapy, Experimental Pharmacology, Toxicological Mechanism +16